Growth factor for therapeutic angiogenesis in ischemic heart disease: A meta-analysis of randomized controlled trials
Aim: This study was designed to systematically evaluate the effects of growth factor (GF) for therapeutic angiogenesis on ischemic heart disease (IHD) by pooling the results of randomized controlled trials (RCTs).Methods and Results: PubMed, EMBASE, and CENTRAL databases were searched from inception...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-12-01
|
| Series: | Frontiers in Cell and Developmental Biology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fcell.2022.1095623/full |
| _version_ | 1811185045603352576 |
|---|---|
| author | Ling Tan Lin-Zi Long Hong-Zheng Li Hong-Zheng Li Wen-Wen Yang Yu-Xuan Peng Yu-Xuan Peng Jie-Ming Lu Jie-Ming Lu Fei-Fei Liao Fei-Fei Liao Xiao-Chang Ma Xiao-Chang Ma Hua Qu Hua Qu Chang-Geng Fu Chang-Geng Fu Shan-Shan Zhang |
| author_facet | Ling Tan Lin-Zi Long Hong-Zheng Li Hong-Zheng Li Wen-Wen Yang Yu-Xuan Peng Yu-Xuan Peng Jie-Ming Lu Jie-Ming Lu Fei-Fei Liao Fei-Fei Liao Xiao-Chang Ma Xiao-Chang Ma Hua Qu Hua Qu Chang-Geng Fu Chang-Geng Fu Shan-Shan Zhang |
| author_sort | Ling Tan |
| collection | DOAJ |
| description | Aim: This study was designed to systematically evaluate the effects of growth factor (GF) for therapeutic angiogenesis on ischemic heart disease (IHD) by pooling the results of randomized controlled trials (RCTs).Methods and Results: PubMed, EMBASE, and CENTRAL databases were searched from inception to October 2022. RCTs, investigating the effects of GF therapy on IHD, were included. The risk bias of included study was assessed according to Cochrane tool. Weighted mean difference (WMD), calculated with fixed effect model or random effect model, was used to evaluate the effects of GF therapy on left ventricular ejection fraction (LVEF) and Canadian Cardiovascular Society (CCS) angina class. Relative risk (RR) was used to evaluate the effects of GF therapy on all-cause mortality, major adverse cardiovascular events (MACE) and revascularization. Meta-analysis, meta-regression analysis and publication bias analysis were performed by RevMan 5.3 or Stata 15.1 software. Twenty-nine studies involving 2899 IHD patients (1,577 patients in GF group and 1,322 patients in control group) were included. Compared with the control group, GF therapy did not reduce all-cause mortality (RR: 0.82; 95% CI: 0.54–1.24; p = 0.341), MACE [(RR: 0.83; 95% CI: 0.61–1.12; p = 0.227), revascularization (RR: 1.27, 95% CI: 0.82–1.96, p = 0.290) and CCS angina class (WMD: −0.08, 95% CI: −0.36 to 0.20, p = 0.560). However, GF therapy could increase LVEF during short-term follow-up (<1 year).Conclusion: GF for therapeutic angiogenesis was beneficial for increasing LVEF during short-term follow-up (<1 year), however, the therapy was not efficacious in decreasing all-cause mortality, MACE and revascularization. |
| first_indexed | 2024-04-11T13:22:35Z |
| format | Article |
| id | doaj.art-b03ef2e8fb6743518a999ec6ab5a070d |
| institution | Directory Open Access Journal |
| issn | 2296-634X |
| language | English |
| last_indexed | 2024-04-11T13:22:35Z |
| publishDate | 2022-12-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Cell and Developmental Biology |
| spelling | doaj.art-b03ef2e8fb6743518a999ec6ab5a070d2022-12-22T04:22:09ZengFrontiers Media S.A.Frontiers in Cell and Developmental Biology2296-634X2022-12-011010.3389/fcell.2022.10956231095623Growth factor for therapeutic angiogenesis in ischemic heart disease: A meta-analysis of randomized controlled trialsLing Tan0Lin-Zi Long1Hong-Zheng Li2Hong-Zheng Li3Wen-Wen Yang4Yu-Xuan Peng5Yu-Xuan Peng6Jie-Ming Lu7Jie-Ming Lu8Fei-Fei Liao9Fei-Fei Liao10Xiao-Chang Ma11Xiao-Chang Ma12Hua Qu13Hua Qu14Chang-Geng Fu15Chang-Geng Fu16Shan-Shan Zhang17Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, ChinaXiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, ChinaXiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, ChinaGraduate School of Beijing University of Chinese Medicine, Beijing, ChinaXiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, ChinaXiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, ChinaGraduate School of Beijing University of Chinese Medicine, Beijing, ChinaXiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, ChinaGraduate School of Beijing University of Chinese Medicine, Beijing, ChinaXiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, ChinaGraduate School of Beijing University of Chinese Medicine, Beijing, ChinaXiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, ChinaNational Cardiovascular Clinical Medical Research Center of TCM, Beijing, ChinaXiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, ChinaNational Cardiovascular Clinical Medical Research Center of TCM, Beijing, ChinaXiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, ChinaNational Cardiovascular Clinical Medical Research Center of TCM, Beijing, ChinaBeijing Xibeiwang Town Community Health Service Center, Beijing, ChinaAim: This study was designed to systematically evaluate the effects of growth factor (GF) for therapeutic angiogenesis on ischemic heart disease (IHD) by pooling the results of randomized controlled trials (RCTs).Methods and Results: PubMed, EMBASE, and CENTRAL databases were searched from inception to October 2022. RCTs, investigating the effects of GF therapy on IHD, were included. The risk bias of included study was assessed according to Cochrane tool. Weighted mean difference (WMD), calculated with fixed effect model or random effect model, was used to evaluate the effects of GF therapy on left ventricular ejection fraction (LVEF) and Canadian Cardiovascular Society (CCS) angina class. Relative risk (RR) was used to evaluate the effects of GF therapy on all-cause mortality, major adverse cardiovascular events (MACE) and revascularization. Meta-analysis, meta-regression analysis and publication bias analysis were performed by RevMan 5.3 or Stata 15.1 software. Twenty-nine studies involving 2899 IHD patients (1,577 patients in GF group and 1,322 patients in control group) were included. Compared with the control group, GF therapy did not reduce all-cause mortality (RR: 0.82; 95% CI: 0.54–1.24; p = 0.341), MACE [(RR: 0.83; 95% CI: 0.61–1.12; p = 0.227), revascularization (RR: 1.27, 95% CI: 0.82–1.96, p = 0.290) and CCS angina class (WMD: −0.08, 95% CI: −0.36 to 0.20, p = 0.560). However, GF therapy could increase LVEF during short-term follow-up (<1 year).Conclusion: GF for therapeutic angiogenesis was beneficial for increasing LVEF during short-term follow-up (<1 year), however, the therapy was not efficacious in decreasing all-cause mortality, MACE and revascularization.https://www.frontiersin.org/articles/10.3389/fcell.2022.1095623/fullgrowth factortherapeutic angiogenesisischemic heart diseasemeta-analysisrandomized controlled study |
| spellingShingle | Ling Tan Lin-Zi Long Hong-Zheng Li Hong-Zheng Li Wen-Wen Yang Yu-Xuan Peng Yu-Xuan Peng Jie-Ming Lu Jie-Ming Lu Fei-Fei Liao Fei-Fei Liao Xiao-Chang Ma Xiao-Chang Ma Hua Qu Hua Qu Chang-Geng Fu Chang-Geng Fu Shan-Shan Zhang Growth factor for therapeutic angiogenesis in ischemic heart disease: A meta-analysis of randomized controlled trials Frontiers in Cell and Developmental Biology growth factor therapeutic angiogenesis ischemic heart disease meta-analysis randomized controlled study |
| title | Growth factor for therapeutic angiogenesis in ischemic heart disease: A meta-analysis of randomized controlled trials |
| title_full | Growth factor for therapeutic angiogenesis in ischemic heart disease: A meta-analysis of randomized controlled trials |
| title_fullStr | Growth factor for therapeutic angiogenesis in ischemic heart disease: A meta-analysis of randomized controlled trials |
| title_full_unstemmed | Growth factor for therapeutic angiogenesis in ischemic heart disease: A meta-analysis of randomized controlled trials |
| title_short | Growth factor for therapeutic angiogenesis in ischemic heart disease: A meta-analysis of randomized controlled trials |
| title_sort | growth factor for therapeutic angiogenesis in ischemic heart disease a meta analysis of randomized controlled trials |
| topic | growth factor therapeutic angiogenesis ischemic heart disease meta-analysis randomized controlled study |
| url | https://www.frontiersin.org/articles/10.3389/fcell.2022.1095623/full |
| work_keys_str_mv | AT lingtan growthfactorfortherapeuticangiogenesisinischemicheartdiseaseametaanalysisofrandomizedcontrolledtrials AT linzilong growthfactorfortherapeuticangiogenesisinischemicheartdiseaseametaanalysisofrandomizedcontrolledtrials AT hongzhengli growthfactorfortherapeuticangiogenesisinischemicheartdiseaseametaanalysisofrandomizedcontrolledtrials AT hongzhengli growthfactorfortherapeuticangiogenesisinischemicheartdiseaseametaanalysisofrandomizedcontrolledtrials AT wenwenyang growthfactorfortherapeuticangiogenesisinischemicheartdiseaseametaanalysisofrandomizedcontrolledtrials AT yuxuanpeng growthfactorfortherapeuticangiogenesisinischemicheartdiseaseametaanalysisofrandomizedcontrolledtrials AT yuxuanpeng growthfactorfortherapeuticangiogenesisinischemicheartdiseaseametaanalysisofrandomizedcontrolledtrials AT jieminglu growthfactorfortherapeuticangiogenesisinischemicheartdiseaseametaanalysisofrandomizedcontrolledtrials AT jieminglu growthfactorfortherapeuticangiogenesisinischemicheartdiseaseametaanalysisofrandomizedcontrolledtrials AT feifeiliao growthfactorfortherapeuticangiogenesisinischemicheartdiseaseametaanalysisofrandomizedcontrolledtrials AT feifeiliao growthfactorfortherapeuticangiogenesisinischemicheartdiseaseametaanalysisofrandomizedcontrolledtrials AT xiaochangma growthfactorfortherapeuticangiogenesisinischemicheartdiseaseametaanalysisofrandomizedcontrolledtrials AT xiaochangma growthfactorfortherapeuticangiogenesisinischemicheartdiseaseametaanalysisofrandomizedcontrolledtrials AT huaqu growthfactorfortherapeuticangiogenesisinischemicheartdiseaseametaanalysisofrandomizedcontrolledtrials AT huaqu growthfactorfortherapeuticangiogenesisinischemicheartdiseaseametaanalysisofrandomizedcontrolledtrials AT changgengfu growthfactorfortherapeuticangiogenesisinischemicheartdiseaseametaanalysisofrandomizedcontrolledtrials AT changgengfu growthfactorfortherapeuticangiogenesisinischemicheartdiseaseametaanalysisofrandomizedcontrolledtrials AT shanshanzhang growthfactorfortherapeuticangiogenesisinischemicheartdiseaseametaanalysisofrandomizedcontrolledtrials |